Stem Cell Transplantation

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

Lenalidomide After ASCT Prolongs Time to Progression in Multiple Myeloma

By

Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

Induction Regimens for Untreated Multiple Myeloma Compared for ORR, OS, PFS

By

Comparison study demonstrates early response and survival benefits of VTD, VTDC, and TAD regimens in transplant-eligible patients with newly diagnosed multiple myeloma.

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

Nivolumab Improves Clinical Outcomes in Patients With Relapsed-Refractory Hodgkin Lymphoma After ASCT, Brentuximab Vedotin

By

Study reports that patients with classic relapsed/refractory Hodgkin lymphoma who received nivolumab after ASCT experienced high rates of response regardless of previous history with brentuximab vedotin.

Stem Cell Transplant Patients Benefit From Inpatient Palliative Care

Stem Cell Transplant Patients Benefit From Inpatient Palliative Care

By

Palliative care added to transplant care improved relief from depression and PTSD symptoms following hematopoietic stem cell transplantation.

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

Guideline-driven Initiative Improves Pneumococcal Vaccination Rates Among aHSCT Recipients

By

A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

Novel Approach Prevents GVHD After Hematopoietic Stem Cell Transplantation

By

An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Combination Therapy Plus Stem-Cell Tx Ups PFS in Multiple Myeloma

Patients with myeloma that underwent transplantation in addition to RVD had significantly longer median progression-free survival compared to the group that received RVD alone.

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

Letermovir Reduces CMV Infection, Improves Survival After Stem Cell Transplantation

By

A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

By

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

By

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Blood-Forming Stem Cell Transplants (Fact Sheet)

Blood-Forming Stem Cell Transplants (Fact Sheet)

This fact sheet reviews bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) as they relate to the cancer treatment.

Pretransplant Depression Associated With Worse Overall Survival

Pretransplant Depression Associated With Worse Overall Survival

By

An assessment of depression in patients before autologous or allogeneic HCT demonstrated that the condition impacts overall survival and risk of GVDH in patients with hematologic malignancies.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

By

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

By

Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

Meta-analysis Confirms Lenalidomide Maintenance Prolongs Overall Survival in Multiple Myeloma

Meta-analysis Confirms Lenalidomide Maintenance Prolongs Overall Survival in Multiple Myeloma

By

Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.

Upfront ASCT Preferred Treatment for Younger Patients With Newly Diagnosed Multiple Myeloma

Upfront ASCT Preferred Treatment for Younger Patients With Newly Diagnosed Multiple Myeloma

By

Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

By

Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.

Study Assesses Risk Factors for Depression Among HSCT Survivors

Study Assesses Risk Factors for Depression Among HSCT Survivors

By

Current presence of pain was associated with both greater depression and fatigue in survivors of hematopoietic stem cell transplantation (HSCT).

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

By

For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

By

For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.

Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)

By

More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.

Sleep Deprivation Affects Stem Cells and Reduces Transplant Efficiency

By

A sleep deficit of just 4 hours affects the ability of blood and immune-system stem cells to migrate to the proper spots in the bone marrow of recipient mice and churn out the cell types necessary to reconstitute a damaged immune system by as much as 50%.

High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With Amyloidosis

By

Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.

Researchers discover a potential biomarker for AML relapse after stem cell transplant

By

Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.

Stem cell transplantation improves outcomes for children with rare form of leukemia

Stem cell transplantation improves outcomes for children with rare form of leukemia

By

Greatly improved outcomes have been observed in using stem cell transplantation to treat patients with juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs